Walsh & Associates’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$192K Sell
734
-74
-9% -$19K 0.15% 56
2026
Q2
$203K Buy
808
+165
+26% +$35.5K 0.17% 55
2026
Q1
$140K Buy
643
+2
+0.3% +$444 0.14% 62
2025
Q4
$146K Hold
641
– – 0.14% 62

Other funds holding ABBV

Walsh & Associates's ABBV Position: Q3 2026 in Review

Walsh & Associates reduced its AbbVie (ABBV) stake by 9.2% in Q3 2026, selling an estimated $19K and leaving 734 shares worth $192K. The position accounts for 0.15% of the portfolio, ranked #56.

Walsh & Associates first reported a position in ABBV in Q4 2025 and has held it in 4 quarters since. The position peaked at $203K in Q2 2026. 4,281 funds tracked by Wall St. Rank hold ABBV as of Q3 2026.

  • Walsh & Associates held 734 shares of AbbVie worth $192K as of Q3 2026.
  • Walsh & Associates sold 74 AbbVie shares in Q3 2026, an estimated $19K.
  • AbbVie made up 0.15% of Walsh & Associates's portfolio in Q3 2026, its #56 holding.
  • Walsh & Associates first reported a position in AbbVie in Q4 2025 and has held it in 4 quarters since.
  • Walsh & Associates's AbbVie position peaked at $203K in Q2 2026.
  • 4,281 funds tracked by Wall St. Rank held AbbVie as of Q3 2026.

Based on Walsh & Associates's 13F filing for Q3 2026, filed 9 Nov 2026.